LAVA Therapeutics (LVTX) Institutional Ownership $1.43 -0.03 (-2.05%) Closing price 03:50 PM EasternExtended Trading$1.46 +0.03 (+1.75%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for LAVA Therapeutics (NASDAQ:LVTX)Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$4.57MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$773.17K Get LVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling LAVA Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LVTX Institutional Buying and Selling by Quarter LAVA Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2025Bruce & Co. Inc.521,874$663K0.2%-32.4%1.984% 5/13/2025Lepercq De Neuflize Asset Management LLC23,000$29K0.0%N/A0.087% 5/8/2025XTX Topco Ltd24,307$31K0.0%N/A0.092% 5/7/2025BML Capital Management LLC1,960,610$2.49M1.9%N/A7.453% 2/17/2025Two Sigma Investments LP48,772$46K0.0%-52.5%0.186% 2/17/2025Sanofi1,919,455$1.83M1.0%N/A7.301% 2/17/2025Sphera Funds Management LTD.126,328$120K0.0%-13.7%0.481% 2/17/2025BNP Paribas Financial Markets41,800$40K0.0%N/A0.159% 11/20/2024Virtu Financial LLC19,103$32K0.0%N/A0.075% 11/15/2024Sphera Funds Management LTD.146,457$243K0.0%-60.2%0.000% Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2024Walleye Capital LLC14,762$25K0.0%-42.5%0.000% 10/8/2024Pathway Financial Advisors LLC102,500$170K0.0%+70.8%0.404% 8/12/2024XTX Topco Ltd30,807$55K0.0%N/A0.122% 7/24/2024Pathway Financial Advisors LLC60,000$108K0.0%+328.6%0.000% 4/10/2024Pathway Financial Advisors LLC14,000$47K0.0%N/A0.000% 5/12/2023Bruce & Co. Inc.671,874$1.12M0.3%+571.9%2.650% 2/10/2023PNC Financial Services Group Inc.50,000$175K0.0%N/A0.197% 2/1/2023Bank of Montreal Can89,600$530K0.0%N/A0.353% 11/14/2022UBS Oconnor LLC75,000$343K0.0%N/A0.296% 10/28/2022Silverarc Capital Management LLC610,809$2.79M0.9%N/A2.409% 8/16/2022DAFNA Capital Management LLC128,335$379K0.1%-7.9%0.506% 8/15/2022Nantahala Capital Management LLC322,980$953K0.0%-3.3%1.274% 2/14/2022Point72 Asset Management L.P.119,152$655K0.0%-3.8%0.470% 11/15/2021Point72 Asset Management L.P.123,911$734K0.0%N/A0.489% 11/15/2021AXA S.A.229,121$1.36M0.0%+3.8%0.904% 11/12/2021Falcon Edge Capital LP140,229$830K0.1%-3.2%0.553% 8/17/2021Woodline Partners LP86,904$946K0.0%-23.3%0.343% 8/17/2021Millennium Management LLC138,831$1.51M0.0%-38.6%0.548% 8/16/2021Redmile Group LLC2,816,196$30.64M0.5%-0.3%11.108% 8/13/2021Geode Capital Management LLC12,997$141K0.0%N/A0.051% 8/11/2021Bank of New York Mellon Corp25,288$275K0.0%-26.3%0.100% 8/10/2021Nicholas Investment Partners LP781,867$8.51M0.5%-4.0%3.084% 8/2/2021New York State Common Retirement Fund19,136$208K0.0%-26.3%0.075% 5/27/2021Davidson Kempner Capital Management LP2,000$30K0.0%N/A0.008% 5/18/2021Millennium Management LLC226,205$3.44M0.0%N/A0.892% 5/18/2021Point72 Asset Management L.P.5,561$84K0.0%N/A0.022% 5/18/2021Tudor Investment Corp Et Al19,614$298K0.0%N/A0.077% 5/18/2021Citadel Advisors LLC60,442$918K0.0%N/A0.238% 5/13/2021Bank of New York Mellon Corp34,319$521K0.0%N/A0.135% (Data available from 1/1/2016 forward) LVTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LVTX shares? During the previous two years, 11 institutional investors and hedge funds held shares of LAVA Therapeutics. The most heavily invested institutionals were BML Capital Management LLC ($2.49M), Sanofi ($1.83M), Bruce & Co. Inc. ($663K), Pathway Financial Advisors LLC ($170K), Sphera Funds Management LTD. ($120K), Two Sigma Investments LP ($46K), and BNP Paribas Financial Markets ($40K).Learn more on LAVA Therapeutics' institutional investors. Which institutional investors have been buying LAVA Therapeutics' stock? The following institutional investors have purchased LAVA Therapeutics' stock in the last 24 months: BML Capital Management LLC ($1.96M), Sanofi ($1.92M), Pathway Financial Advisors LLC ($102.50K), XTX Topco Ltd ($55.11K), BNP Paribas Financial Markets ($41.80K), Lepercq De Neuflize Asset Management LLC ($23K), and Virtu Financial LLC ($19.10K). How much institutional buying is happening at LAVA Therapeutics? Institutional investors have bought a total of 4,061,582 shares in the last 24 months. This purchase volume represents approximately $4.57M in transactions. Which of LAVA Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold LAVA Therapeutics stock in the last 24 months: Bruce & Co. Inc. ($250K), Sphera Funds Management LTD. ($241.25K), Two Sigma Investments LP ($53.99K), and Walleye Capital LLC ($10.91K). How much institutional selling is happening at LAVA Therapeutics? Institutional investors have sold a total of 556,161 shares in the last 24 months. This volume of shares sold represents approximately $773.17K in transactions. Related Companies Immuneering Major Shareholders Enanta Pharmaceuticals Major Shareholders Spero Therapeutics Major Shareholders Lexeo Therapeutics Major Shareholders Theratechnologies Major Shareholders Greenwich LifeSciences Major Shareholders Rapt Therapeutics Major Shareholders Inhibikase Therapeutics Major Shareholders Molecular Partners Major Shareholders Lyell Immunopharma Major Shareholders This page (NASDAQ:LVTX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
